The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Multi-Steroid Profiling and Machine Learning Reveal Androgens as Candidate Biomarkers for Endometrial Cancer Diagnosis: A Case-Control Study
Open accessAbstract
Objective: To evaluate the diagnostic and prognostic potential of preoperative serum steroid levels in endometrial cancer (EC) alone and in combination with clinical parameters and biomarkers CA-125 and HE4. Methods: This single-center observational study included 62 patients with EC and 70 controls with benign uterine conditions who underwent surgery between June 2012 and February 2020. Preoperative serum levels of classic androgens, 11-oxyandrogens, glucocorticoids and mineralocorticoids were measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Machine learning was used to assess their diagnostic and prognostic value alone and combined with clinical parameters and tumor biomarkers. Results: Patients with EC had significantly higher serum levels of classic androgens (androstenedione, testosterone), 11-oxyandrogens (11β-hydroxy-androstenedione, 11β-hydroxy-testosterone) and glucocorticoids (17α-hydroxy-progesterone, 11-deoxycortisol) compared to controls. While individual steroids had limited diagnostic value, a multivariate model including classic androgens, CA-125, HE4, BMI and parity achieved an AUC 0.87, 79.1% sensitivity and 74.7% specificity in distinguishing EC from benign uterine condition. This model outperformed our previously published model based on CA-125, HE4 and BMI (AUC: 0.81, p < 0.0001). Prognostically, HE4 was the strongest marker for lymphovascular space invasion (LVSI) (AUC: 0.79) and deep myometrial invasion (MI) (AUC: 0.71). Among steroids, androstenedione was the most predictive of LVSI (AUC: 0.67), while 11β-hydroxy-testosterone was the strongest predictor of deep MI (AUC: 0.64). Conclusions: Patients with EC exhibit distinct steroid hormone profiles. While steroids alone offer modest diagnostic and prognostic value, integrating them into multivariate models improves diagnostic accuracy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Logistic regression models for predicting EC probability (cases, n = 62; controls, n = 70): (a) Univariate models with AUC above 0.6. (b) Multivariate models: Knific 2017 [23] = 0.884 (ln[CA-125]) + 2.402 (ln[HE4]) + 3.142 (ln[BMI]) − 23.284; model with 5 best variables = 2.868 (ln[HE4]) + 1.116 (ln[Androgen pool]) + 2.929 (ln[BMI]) − 0.835 (Parity) + 1.292 (ln[CA-125]) − 27.214. Data in brackets represent 95% confidence intervals (CI). Light grey color around the ROC curves shows standard deviation. 11OHA4, 11β-hydroxy-androstenedione; 11OHT, 11β-hydroxy-testosterone; AUC, area under the receiver operating curve; BMI, body mass index; CA-125, cancer antigen 125; HE4, human epididymis protein 4; ln, natural logarithm; ROC, receiver operator curve; T, testosterone.](https://figures.cochat.ai/paper-figures/55769ac84918468998b9578c87877874/multi-steroid-profiling-and-machine-learning-reveal-androgens-as-candidate-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · cited 1×
“Endometrial cancer (EC) is the sixth most common cancer affecting women, with approximately 420,000 new cases diagnosed worldwide in 2022 [1].”
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · cited 1×
“Its incidence is rising globally, driven by factors such as population growth, aging, increasing obesity rates and a higher human development index [2].”
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655 · cited 1×
“The minimum sample size for the logistic regression models was calculated based on Peduzzi et al. [28] using the formula: N = 10 × k/p, where N is the minimum required number of samples, k is the number of covariates and p is the smallest proportion of negative or positive cases in the cohort.”
Building Predictive Models in R Using the caret Package
Kuhn, M. (2008) · Journal of Statistical Software · doi:10.18637/jss.v028.i05 · Cited by 8,863 · cited 1×
“Machine learning was performed in R Studio (version 4.3.0 or higher) using caret library [27].”
InfluentialIntegrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784 · cited 2×
“The first three groups mostly include low-grade, clinically favorable endometrioid tumors, while TP53-alt tumors are typically high-grade endometrioid or serous with a higher risk of recurrence [4–6].”
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationBhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707 · cited 1×
“Given that higher BMI is characteristic of patients with EC [36], it is plausible that expanded adipose depots in these individuals further drive alterations in both classic and 11-oxyandrogen levels.”
Crosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,333
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160 · cited 1×
“Microbial enzymes can generate androgens such as DHEA and T from precursors like pregnenolone and 17 α -hydroxy- pregnenolone [29] and may also contribute to the production of 11-oxyandrogens from cortisol or other C21 steroids [30–32].”
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652 · cited 3×
“However, no blood-based diagnostic tests for EC are currently included in European clinical guidelines [5].”
InfluentialAssociation of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.2820 · Cited by 426
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323 · cited 1×
“Microbial enzymes can generate androgens such as DHEA and T from precursors like pregnenolone and 17 α -hydroxy- pregnenolone [29] and may also contribute to the production of 11-oxyandrogens from cortisol or other C21 steroids [30–32].”
Allen, N. E., Key, T. J., Dossus, L., Rinaldi, S., Cust, A., Lukanova, A., Peeters, P. H., Onland-Moret, N. C., Lahmann, P. H., Berrino, F., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0064 · Cited by 268 · cited 2×
“Although Dahmani et al. reported that systemic levels of 11-oxyandrogens decline after tumor removal, suggesting tumor-driven regulation [42], our recent findings show that”
Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women
Lukanova, A., Lundin, E., Micheli, A., Arslan, A., Ferrari, P., Rinaldi, S., Krogh, V., Lenner, P., Shore, R. E., Biessy, C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.11529 · Cited by 239 · cited 1×
“These diagnostic improvements align with extensive epidemiological data showing androgens, like DHEA-sulfate [40,41], A4 [40,41], T [41] and some androgen glucuronides [40] to be elevated in patients with EC, although not all studies agree [40,42,43].”
11-Oxygenated androgens in health and disease
Turcu, A. F., Rege, J., Auchus, R. J., & Rainey, W. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0336-x · Cited by 217 · cited 1×
“Indeed, the adipose tissue has been shown to express steroid metabolizing enzymes, like AKR1C3 [37–39].”
O’Reilly, M. W., Kempegowda, P., Walsh, M., Taylor, A. E., Manolopoulos, K. N., Allwood, J. W., Semple, R. K., Hebenstreit, D., Dunn, W. B., Tomlinson, J. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00947 · Cited by 215
Self-citationTorres, A., Torres, K., Pesci, A., Ceccaroni, M., Paszkowski, T., Cassandrini, P. A., Zamboni, G., & Maciejewski, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27840 · Cited by 164 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Accuracy of Endometrial Sampling in Endometrial Carcinoma
Visser, N. C. M., Reijnen, C., Massuger, L. F. A. G., Nagtegaal, I. D., Bulten, J., & Pijnenborg, J. M. A. (2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002261 · Cited by 157
Predictors of final histology in patients with endometrial cancer
Frumovitz, M., Singh, D. K., Meyer, L., Smith, D. H., Wertheim, I., Resnik, E., & Bodurka, D. C. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.016 · Cited by 145 · cited 1×
“However, risk stratification remains imprecise, as biopsy results often do not align with post-hysterectomy findings [16–18], highlighting the need for more accurate prognostic tools.”
Serum HE4 as a prognostic marker in endometrial cancer — A population based study
Brennan, D. J., Hackethal, A., Metcalf, A., Coward, J. I. G., Ferguson, K., Oehler, M. K., Quinn, M. A., Janda, M., Leung, Y. C., Freemantle, M., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.10.036 · Cited by 107 · cited 2×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
Long, B. J., Clarke, M. A., Morillo, A. D. M., Wentzensen, N., & Bakkum-Gamez, J. N. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.032 · Cited by 99 · cited 1×
“%) in postmenopausal women, leading to a high rate of false positives [9].”
Metabolomic Signature of Endometrial Cancer
Troisi, J., Sarno, L., Landolfi, A., Scala, G., Martinelli, P., Venturella, R., Cello, A. D., Zullo, F., & Guida, M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00503 · Cited by 97
HE4 as a Biomarker for Endometrial Cancer
Behrouzi, R., Barr, C. E., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13194764 · Cited by 89 · cited 1×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
Expression of androgen receptor and 5α‐reductases in the human normal endometrium and its disorders
Ito, K., Suzuki, T., Akahira, J., Moriya, T., Kaneko, C., Utsunomiya, H., Yaegashi, N., Okamura, K., & Sasano, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10394 · Cited by 88
Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer
Šmuc, T., & Rižner, T. L. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.019 · Cited by 86
Self-citationKamal, A. M., Bulmer, J. N., DeCruze, S. B., Stringfellow, H. F., Martin-Hirsch, P., & Hapangama, D. K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.16 · Cited by 84
Androgen receptor as potential therapeutic target in metastatic endometrial cancer
Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Oyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K., Salvesen, H. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10334 · Cited by 75 · cited 1×
“Moreover, endometrial tumors, especially endometrioid ones, are known to express steroid-metabolizing enzymes and receptors [44–50], and to form locally androgens, 11-oxyandrogens and estrogens [35,51], suggesting that this intra-tumoral activity may also contribute to the improved diagnostic…”
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer
Ashley, C. W., Selenica, P., Patel, J., Wu, M. K. Y., Ninčević, J., Lakhman, Y., Zhou, Q. C., Shah, R. H., Berger, M. F., Paula, A. D. C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1134 · Cited by 74 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Antonsen, S. L., Høgdall, E. V. S., Christensen, I. J., Lydolph, M. C., Tabor, A., Jakobsen, A. L., Fagö-Olsen, C. L., Andersen, E., Jochumsen, K. M., & Høgdall, C. K. (2013) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12235 · Cited by 71
IHATA, Y., Miyagi, E., Numazaki, R., Muramatsu, T., Imaizumi, A., Yamamoto, H., Yamakado, M., Okamoto, N., & Hirahara, F. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0565-2 · Cited by 68
Knific, T., Vouk, K., Smrkolj, Š., Prehn, C. P., Adamski, J., & Rižner, T. L. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.01.012 · Cited by 65 · cited 2×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Self-citationWinter, J., Morris, G. N., Locascio, S., Bokkenheuser, V. D., Mosbach, E. H., Cohen, B. I., & Hylemon, P. B. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37722-1 · Cited by 64
Audet-Delage, Y., Villeneuve, L., Grégoire, J., Plante, M., & Guillemette, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00087 · Cited by 57
Devendran, S., Méndez–García, C., & Ridlon, J. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074914 · Cited by 55
Multi-steroid profiling by UHPLC-MS/MS with post-column infusion of ammonium fluoride
Schiffer, L., Shaheen, F., Gilligan, L. C., Storbeck, K.-H., Hawley, J. M., Keevil, B. G., Arlt, W., & Taylor, A. E. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123413 · Cited by 52 · cited 3×
“Steroids were extracted from serum samples by liquid–liquid extraction, as described previously [25,26].”
Self-citationCheng, S.-C., Chen, K., Chiu, C., Lu, K., Lu, H., Chiang, M., Tsai, C., Lo, C.-J., Cheng, M., Chang, T., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1609-z · Cited by 48
Troisi, J., Raffone, A., Travaglino, A., Belli, G., Belli, C., Anand, S. K., Giugliano, L., Cavallo, P., Scala, G., Symes, S. J. K., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.18327 · Cited by 48
Reijnen, C., Visser, N. C. M., Kasius, J. C., Boll, D., Geomini, P. M. A. J., Ngo, H., van Hamont, D., Pijlman, B. M., Vos, M. C., Bulten, J., et al. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e70 · Cited by 47 · cited 1×
“Additionally, biomarkers such as cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4) have been shown to improve preoperative risk stratification [20–22].”
Troisi, J., Mollo, A., Lombardi, M., Scala, G., Richards, S. M., Symes, S. J. K., Travaglino, A., Neola, D., Laurentiis, U. D., Insabato, L., et al. (2022) · Biomolecules · doi:10.3390/biom12091229 · Cited by 46 · cited 2×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer
Knific, T., Osredkar, J., Smrkolj, Š., Tonin, I., Vouk, K., Blejec, A., Grazio, S. F., & Rižner, T. L. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.130 · Cited by 44 · cited 4×
“Differences in HE4 ′ s performance for LVSI (AUC: 0.810) and deep MI (AUC: 0.776) compared to the Knific et al. study [23] were most likely due to differences in 20 samples between this cohort and the original one.”
InfluentialSelf-citationMichels, K. A., Brinton, L. A., Wentzensen, N., Pan, K., Chen, C., Anderson, G. L., Pfeiffer, R. M., Xu, X., Rohan, T. E., & Trabert, B. L. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz029 · Cited by 44 · cited 1×
“These diagnostic improvements align with extensive epidemiological data showing androgens, like DHEA-sulfate [40,41], A4 [40,41], T [41] and some androgen glucuronides [40] to be elevated in patients with EC, although not all studies agree [40,42,43].”
Sinreih, M., Hevir, N., & Rižner, T. L. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.11.012 · Cited by 42
Self-citationSchiffer, L., Kempegowda, P., Sitch, A. J., Adaway, J. E., Shaheen, F., Ebbehoj, A., Singh, S., McTaggart, M. P., O’Reilly, M. W., Prete, A., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac017 · Cited by 42 · cited 1×
“Steroids were extracted from serum samples by liquid–liquid extraction, as described previously [25,26].”
Self-citationIdentification and validation of serum metabolite biomarkers for endometrial cancer diagnosis
Liu, W., Ma, J., Zhang, J., Cao, J., Hu, X., Huang, Y., Wang, R., Wu, J., Di, W. J., Qian, K., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00033-1 · Cited by 40 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Endometrial cancer: A systematic review of HE4, REM and REM-B
Degez, M., Caillon, H., Chauviré-Drouard, A., Leroy, M., Lair, D., Winer, N., Thubert, T., & Dochez, V. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.029 · Cited by 36 · cited 1×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
Li, Y., Liu, G., Gong, R., & Xi, Y. (2023) · Current Microbiology · doi:10.1007/s00284-023-03361-6 · Cited by 36 · cited 1×
“The distinct alterations in the gut microbiota in patients with EC [33], might contribute to altered systemic steroid levels as well, although this need to be investigated further.”
Metabolomic prediction of endometrial cancer
Bahado-Singh, R. O., Lugade, A. A., Field, J. B., Al-Wahab, Z. R., Han, B., Mandal, R., Bjorndahl, T. C., Türkoğlu, O., Graham, S. F., Wishart, D. S., et al. (2017) · Metabolomics · doi:10.1007/s11306-017-1290-z · Cited by 35
Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer
Njoku, K., Campbell, A. E., Geary, B., MacKintosh, M. L., Derbyshire, A. E., Kitson, S., Sivalingam, V. N., Pierce, A., Whetton, A. D., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13040718 · Cited by 35
Ura, B., Biffi, S., Monasta, L., Arrigoni, G., Battisti, I., Lorenzo, G. D., Romano, F., Aloisio, M., Celsi, F., Addobbati, R., et al. (2021) · Cancers · doi:10.3390/cancers13143639 · Cited by 35
Njoku, K., Pierce, A., Chiasserini, D., Geary, B., Campbell, A. E., Kelsall, J., Reed, R., Geifman, N., Whetton, A. D., & Crosbie, E. J. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105064 · Cited by 34 · cited 2×
“…the biomolecules studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating…”
Enroth, S., Berggrund, M., Lycke, M., Lundberg, M., Assarsson, E., Olovsson, M. H., Stålberg, K., Sundfeldt, K., & Gyllensten, U. B. (2018) · Clinical Proteomics · doi:10.1186/s12014-018-9216-y · Cited by 30
Yan, X., Zhao, W., Wei, J., Yao, Y., Sun, G., Wang, L., Zhang, W., Chen, S., Zhou, W., Zhao, H., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33943 · Cited by 29
Are preoperative histology and MRI useful for classification of endometrial cancer risk?
Body, N., Lavoué, V., Kerdaniel, O. D., Foucher, F., Henno, S., Cauchois, A., Laviolle, B., Leblanc, M., & Lévêque, J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2554-0 · Cited by 29 · cited 1×
“However, risk stratification remains imprecise, as biopsy results often do not align with post-hysterectomy findings [16–18], highlighting the need for more accurate prognostic tools.”
Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer
Fan, X., Cao, M., Liu, C., Zhang, C., Li, C., Cheng, W., Zhang, S., Zhang, H., & Zhu, W. (2021) · Cancer Biomarkers · doi:10.3233/cbm-200972 · Cited by 29 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study
Clendenen, T. V., Hertzmark, K., Koenig, K. L., Lundin, E., Rinaldi, S., Johnson, T., Krogh, V., Hallmans, G., Idahl, A., Lukanova, A., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0258-1 · Cited by 28 · cited 1×
“These diagnostic improvements align with extensive epidemiological data showing androgens, like DHEA-sulfate [40,41], A4 [40,41], T [41] and some androgen glucuronides [40] to be elevated in patients with EC, although not all studies agree [40,42,43].”
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas
Hojnik, M., Šuster, N. K., Smrkolj, Š., Grazio, S. F., Verdenik, I., & Rižner, T. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124105 · Cited by 26
Self-citationBarr, C. E., Njoku, K., Jones, E. R., & Crosbie, E. J. (2022) · Diagnostics · doi:10.3390/diagnostics12112834 · Cited by 26 · cited 1×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
Early detection of uterine corpus endometrial carcinoma utilizing plasma cfDNA fragmentomics
Liu, J., Hu, D., Lin, Y., Chen, X., Yang, R., Li, L., Zhan, Y., Bao, H., Zang, L., Zhu, M., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03531-8 · Cited by 26 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Yi, R., Xie, L., Wang, X., Shen, C., Chen, X., & Qiao, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861142 · Cited by 25
Hishinuma, E., Shimada, M., Matsukawa, N., Shima, Y., Li, B., Motoike, I. N., Shibuya, Y., Hagihara, T., Shigeta, S., Tokunaga, H., et al. (2023) · Cancer & Metabolism · doi:10.1186/s40170-023-00317-z · Cited by 25 · cited 1×
“…studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor DNA [84–86].”
Tarney, C. M., Wang, G., Bateman, N. W., Conrads, K. A., Zhou, M., Hood, B. L., Loffredo, J., Tian, C., Darcy, K. M., Hamilton, C. A., et al. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.06.005 · Cited by 24
Romano, A., Rižner, T. L., Werner, H. M. J., Semczuk, A., Lowy, C., Schröder, C., Griesbeck, A., Adamski, J., Fishman, D., & Tokarz, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120178 · Cited by 24 · cited 1×
“These studies explore a wide range of biomolecules across various biological fluids—including plasma, serum, cervicovaginal fluid and uterine aspirates—and increasingly apply machine learning approaches (reviewed in [61,62]).”
Self-citationO’Toole, S. A., Huang, Y., Norris, L., Foley, M. P., Shireen, R., McDonald, S., Kamran, W. M., Ibrahim, N., Ward, M. P., Thompson, C. L., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.11.004 · Cited by 23
Celsi, F., Monasta, L., Arrigoni, G., Battisti, I., Licastro, D., Aloisio, M., Lorenzo, G. D., Romano, F., Ricci, G., & Ura, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042076 · Cited by 22
Zou, J., & Wang, E. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.01.004 · Cited by 21
Blood steroids are associated with prognosis and fat distribution in endometrial cancer
Tangen, I. L., Fasmer, K. E., Konings, G. F. J., Jochems, A., Delvoux, B., Xanthoulea, S., Stokowy, T., Strand, E., Berg, H. F., Auriola, S. O. K., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.024 · Cited by 21 · cited 2×
“For example, Tangen et al. reported that higher preoperative plasma levels of DHEA, DHEA-sulfate, progesterone (and its 21-hydroxylated metabolite) and estrone sulfate were linked to longer overall survival in patients with EC [59].”
Evaluation of complete blood count parameters to predict endometrial cancer
Abide, Ç. Y., Ergen, E. B., Çöğendez, E., Kılıççı, Ç., Uzun, F., Özkaya, E., & Karateke, A. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22438 · Cited by 20
Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling
Forsse, D., Tangen, I. L., Fasmer, K. E., Halle, M. K., Viste, K., Almås, B., Bertelsen, B.-E., Trovik, J., Haldorsen, I. S., & Krakstad, C. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.123 · Cited by 20 · cited 3×
“…levels of 17 α -hydroxyprogesterone and 11-deoxycortisol had increased expression of genes related to cell proliferation, while tumors from patients with high plasma levels of these hormones showed upregulated estrogen signaling and increased expression of genes associated with inflammation [60].”
Molecular classification improves preoperative risk assessment of endometrial cancer
Cabrera, S., Bebia, V., López-Gil, C., Aznar, A. L., Denizli, M., Salazar-Huayna, L., Abdessayed, N., Castellví, J., Colás, E., & Gil‐Moreno, A. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.003 · Cited by 20 · cited 1×
“A recent study found that molecular classification of preoperative biopsy samples, combined with imaging tests, predicts advanced disease more reliably than histotype or grade [19].”
Ura, B., Capaci, V., Aloisio, M., Lorenzo, G. D., Romano, F., Ricci, G., & Monasta, L. (2022) · Biomedicines · doi:10.3390/biomedicines10081857 · Cited by 19 · cited 1×
“…the biomolecules studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor…”
Ronsini, C., Iavarone, I., Vastarella, M. G., Corte, L. D., Andreoli, G., Bifulco, G., Cobellis, L., & FRANCISCIS, P. D. (2024) · Cancers · doi:10.3390/cancers16213567 · Cited by 19 · cited 1×
“Additionally, routine blood count parameters—reflecting systemic immune or inflammatory responses—have shown promising diagnostic potential [87–89].”
Schiffer, L., Oestlund, I., Snoep, J. L., Gilligan, L. C., TAYLOR, A. E. R., Sinclair, A. J., Singhal, R., Freeman, A., Ajjan, R., Tiganescu, A., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202302131r · Cited by 18
Self-citationPavlič, R., Gjorgoska, M., Hafner, E., Sinreih, M., Gajser, K., Poschner, S., Jäger, W. R., & Rižner, T. L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.743403 · Cited by 18
Self-citationPavlič, R., Vidic, S., Anko, M., Knific, T., Büdefeld, T., Marton, K., Sinreih, M., Poschner, S., Jäger, W. R., Frković‐Grazio, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083819 · Cited by 15
Self-citationSchuhn, A., Witte, T., Ward, A., Hauke, J., Baumann, L., Okun, J. G., & Nees, J. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06482-8 · Cited by 15
Tissue-Based Proteomic Profiling in Patients with Hyperplasia and Endometrial Cancer
Akkour, K., Alanazi, I. O., Alfadda, A. A., Alhalal, H., Masood, A., Musambil, M., Rahman, A. M. A., Alwehaibi, M. A., Arafah, M., Bassi, A., et al. (2022) · Cells · doi:10.3390/cells11132119 · Cited by 15 · cited 1×
“…biomolecules studied are proteins (hormones, cancer-associated antigens, plasma glycoproteins, plasma lipoproteins, enzymes, growth factors) [11,63–69], lipids and metabolites (glycerophospholipids, sphingolipids, fatty acids, amino acids) ([12,14,70–81]), micro RNAs [82,83], circulating tumor…”
Rižner, T. L., & Adamski, J. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.09.017 · Cited by 14 · cited 1×
“Sample collection and processing followed a strict standard operating procedure specifically designed for metabolomic studies [24].”
Self-citationProteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique
Ceylan, Y., Akpınar, G., Döğer, E., Kasap, M., Güzel, N., Karaosmanoğlu, K., Köpük, Ş. Y., & Yücesoy, İ. (2019) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2019.101652 · Cited by 13
A metabolomic signature of FIGO stage I and II endometrial cancer
Gu, M., Chen, X., Sun, Y., Wan, L., Shu, H., & Qian, C. (2021) · Neoplasma · doi:10.4149/neo_2021_210306n288 · Cited by 13
He, Y., Wang, J., Ma, C., & Kang, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820971660 · Cited by 12 · cited 1×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
Plotti, F., Capriglione, S., Scaletta, G., Luvero, D., Lopez, S., Nastro, F. F., Terranova, C., Nardone, C. D. C., Montera, R., & Angioli, R. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.03.044 · Cited by 11 · cited 2×
“%) but requires further validation [10].”
Dahmani, C., Caron, P., Simonyan, D., Turcotte, V., Grégoire, J., Plante, M., & Guillemette, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156680 · Cited by 11 · cited 2×
“Moreover, 11-oxyandrogen metabolites appear to carry independent prognostic information: elevated preoperative 11-ketoandrosterone predicted a higher risk of recurrence, while increased postoperative 11-hydroxyandrosterone was associated with both greater recurrence rates and reduced survival [34].”
Lee, M. S., Moon, M. H., Kim, S. Y., Jang, S., Oh, S., & Cho, J. Y. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110276 · Cited by 8 · cited 1×
“Preoperative imaging, such as magnetic resonance imaging (MRI) aids in assessing myometrial and cervical involvement and detecting enlarged lymph nodes and disease spread [15].”
Neilson, A., Jamieson, A., Chiu, D. S., Leung, S., Lum, A. M., Kommoss, S., Huntsman, D. D., Talhouk, A., Gilks, C. B., & McAlpine, J. N. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.12.010 · Cited by 7 · cited 2×
“The best prognostic predictors of LVSI and MI in our cohort were HE4 and CA-125, consistent with prior studies [21,22,52–56] and systematic reviews and meta analyses [57,58], which report strong performance of these markers for LVSI and MI prediction.”
The discovery of biomarkers for endometrial cancer: update over the last years
Rižner, T. L., & Romano, A. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2505546 · Cited by 7 · cited 1×
“These studies explore a wide range of biomolecules across various biological fluids—including plasma, serum, cervicovaginal fluid and uterine aspirates—and increasingly apply machine learning approaches (reviewed in [61,62]).”
Self-citationClinical Correlations between Serological Markers and Endometrial Cancer
Marin, A.-G., Filipescu, A. G., Petca, R., Vlădăreanu, R., & Petca, A. T. (2024) · Cancers · doi:10.3390/cancers16101935 · Cited by 6
Gong, S., Quan, Q., Meng, Y., Wu, J., Yang, S., Hu, J., & Mu, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18016 · Cited by 3
Gjorgoska, M., Šturm, L., & Rižner, T. L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1404804 · Cited by 3 · cited 4×
“Low-grade tumors were more efficient in producing 11KT, a metabolite capable of activating the androgen receptor, which has been associated with better survival outcomes [35].”
InfluentialSelf-citation
Cited by
Steroid hormone profiling reveals altered adrenal androgen production in endometriosis
Simitsidellis, I., Ainslie, R. J., Taylor, A. E., Gilligan, L. C., Shaheen, F., Blanke, S., Anderson, C., Hapangama, D., Arlt, W., Horne, A. W., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag109 · Cited by 1
Self-citation
Metadata
- Authors
- Gjorgoska, M., Taylor, A. E., Smrkolj, Š., & Rižner, T. L.
- Affiliations
- University of Ljubljana (SI)
- University of Birmingham (GB)
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2025-05-16
- Volume
- 17
- Issue
- 10
- Pages
- 1679
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC12110686
- OpenAlex
- W4410445939
- Cited by
- 1
- References
- 90
- Citations by year
- 2026: 1
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DiRROS repository (University of Maribor) (submittedVersion, cc-by)
- dCOBISS.SI Digital Repository (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- Slovenian Research Agency (J3-2535, J3-3069, P1-0390, P3-0449)
- Society of Endocrinology (J3-2535, J3-3069, P1-0390, P3-0449)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- endometrial cancer, androgens, glucocorticoids, mineralocorticoids, androstenedione, CA125, HE4, lymphovascular invasion, deep myometrial invasion, prognostic factors, diagnostic biomarkers, machine learning, multivariate models, parity, body mass index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.